Introduction
B-cell deficiency
CORONAVIRUS, DISEASE, SARS-COV-2 INFECTION, SEVERE ACUTE RESPIRATORY SYNDROME
The coronavirus disease-19 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) prompted the development of several vaccines which protect billions of people from severe course of disease in particular by induction of humoral, i.e., antibody-mediated immunityIn a Phase I trial, our peptide-based T-cell activator CoVac-1 showed a favorable safety profile and induced broad and long-lasting T-cell immunity that by far exceeded T-cell responses after SARS-CoV-2 infection as well as after vaccination with any approved vaccineWe here report the results of the open-label Phase I/II trial evaluating immunogenicity along with safety and reactogenicity of CoVac-1 in the high-risk population of patients with congenital or acquired B-cell deficiency.